Abstract
Historically, myeloablative allogeneic hematopoietic SCT (HSCT) has required prolonged in-patient hospitalization due to the effects of mucosal toxicity and prolonged cytopenias. We explored the safety and feasibility of outpatient management of these patients. A total of 100 consecutive patients underwent a matched-related donor myeloablative allogeneic HSCT for a hematologic malignancy at a single institution. Patients were hospitalized briefly for stem-cell infusion and thereafter only for complications more safely managed in the in-patient setting. The median hospital length of stay from the start of the preparative regimen to day +30 and day +100 post-transplant was 12 and 15 days, respectively. Planned hospital discharge occurred in 79 patients after stem cell infusion. Patients were readmitted to hospital at median of day +7 post transplant, with neutropenic fever being the primary cause for readmission. In total, 18 patients required no in-patient care in the first 100 days. Non-relapse mortality at day 100 and 6 months was 10 and 15%, respectively, for all patients, and 0 and 5%, respectively, for standard risk patients. In summary, outpatient myeloablative allogeneic HSCT with expectant in-patient management can be accomplished safely with low treatment-related morbidity and mortality. Clinical outcomes seem comparable to those reported for traditional in-patient management.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cornelissen JJ, Lowenberg B . Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 2005, 151–155.
Yanada M, Matsuo K, Suzuki T, Naoe T . Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006; 106: 2657–2663.
Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050–1055.
Svahn DM, Ringdén O, Remberger M . Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation 2005; 36: 511–516.
Pavletic ZS, Bishop MR, Tarantolo SR, Martin-Algarra S, Bierman PJ, Vose JM et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol 1997; 15: 1608–1616.
Bennett C, Waters T, Stinson T, Almagor O, Pavletic Z, Tarantolo S et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 555–560.
Gilbert C, Meisenberg B, Vredenburgh J, Ross M, Hussein A, Perfect J et al. Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 1994; 12: 1005–1011.
Peters WP, Ross M, Vredenburgh JJ, Hussein A, Rubin P, Dukelow K et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21: 25–31.
Fernández-Avilés F, Carreras E, Urbano-Ispizua A, Rovira M, MartÃnez C, Gaya A et al. Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. J Clin Oncol 2006; 24: 4855–4861.
Leger C, Sabloff M, McDiarmid S, Bence-Bruckler I, Atkins H, Bredeson C et al. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma. Ann Hematol 2006; 85: 723–729.
Schulmeister L, Quiett K, Mayer K . Quality of life, quality of care, and patient satisfaction: perceptions of patients undergoing outpatient autologous stem cell transplantation. Oncol Nurs Forum 2005; 32: 57–67.
Rovira M . Outpatient management of autologous haematopoietic cell transplantation: the Barcelona experience. Presse Med 2004; 33: 479–481.
Chandrasekar PH, Abraham OC, Klein J, Alangaden G, Chalasani G, Cassells L et al. Low infectious morbidity after intensive chemotherapy and autologous peripheral blood progenitor cell transplantation in the outpatient setting for women with breast cancer. Clin Infect Dis 2001; 32: 546–551.
Meisenberg BR, Ferran K, Hollenbach K, Brehm T, Jollon J, Piro LD . Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant 1998; 21: 927–932.
Glück S, des Rochers C, Cano C, Dorreen M, Germond C, Gill K et al. High-dose chemotherapy followed by autologous blood cell transplantation: a safe and effective outpatient approach. Bone Marrow Transplant 1997; 20: 431–434.
Subirà M, Sureda A, Ancin I, Martino R, Altés A, Brunet S et al. Allogeneic stem cell transplantation with reduced-intensity conditioning is potentially feasible as an outpatient procedure. Bone Marrow Transplant 2003; 32: 869–872.
Maris M, Storb R . Outpatient allografting in hematologic malignancies and nonmalignant disorders—applying lessons learned in the canine model to humans. Cancer Treat Res 2002; 110: 149–175.
Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú OG, Jaime-Pérez JC . Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. Am J Hematol 2001; 66: 241–244.
Rizzo JD, Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB . Outpatient based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? J Clin Oncol 1999; 17: 2811–2818.
Matthews RH, Emami M, Connaghan DG, Holland HK, Morris LE . Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 397–400.
Kaplan EL, Meier P . Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457–481.
Millman Research Report: 2008 US organ tissue transplant cost estimate and discussion. 7 April 2008.
Russell JA, Chaudhry A, Booth K, Brown C, Woodman RC, Valentine K et al. Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: a 10-year experience. Biol Blood Marrow Transplant 2000; 6: 109–114.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Solomon, S., Matthews, R., Barreras, A. et al. Outpatient myeloablative allo-SCT: a comprehensive approach yields decreased hospital utilization and low TRM. Bone Marrow Transplant 45, 468–475 (2010). https://doi.org/10.1038/bmt.2009.234
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2009.234
Keywords
This article is cited by
-
A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe
Bone Marrow Transplantation (2020)
-
Safety and feasibility of outpatient autologous stem cell transplantation in pediatric patients with primary central nervous system tumors
Bone Marrow Transplantation (2019)
-
A scoping review of caregiver burden during allogeneic HSCT: lessons learned and future directions
Bone Marrow Transplantation (2016)
-
Haploidentical Bone Marrow Transplantation in 2015 and Beyond
Current Oncology Reports (2015)
-
General health, symptom occurrence, and self-efficacy in adult survivors after allogeneic hematopoietic stem cell transplantation: a cross-sectional comparison between hospital care and home care
Supportive Care in Cancer (2015)